Increasing Demand for Pork to Augment Growth of Porcine Reproductive and Respiratory Syndrome Vaccine Market

Porcine Reproductive and Respiratory Syndrome Vaccine Market


 Betaarterivirus suid 1, commonly known as porcine reproductive and respiratory syndrome virus, generally causes a respiratory disease of pigs, named porcine reproductive and respiratory syndrome. The disease is caused by a strain of a virus called beta interferon gamma, which attacks the nerve cells in the reproductive organs. When the cells become infected, they attack the ovum causing it to fail, thus stopping the female's reproductive cycle. Thereafter, eggs do not grow in the female and are expelled via the fecal track. Pregnant females are more susceptible to this disease than are naturally pregnant females.

Market Dynamics 

Increasing demand for pork is expected to propel growth of the porcine reproductive and respiratory syndrome vaccine market. For instance, according to the U.S. Department of Agriculture, in the U.S., pork’s export share of production is expected to increase from 22.9% in 2019 to 25.8% in 2020 and in 2021, due primarily to strong exports to China. Moreover, new cases of porcine reproductive and respiratory syndrome are also expected to aid in growth of the market. For instance, in August 2020, Department of Livestock Development, Thailand, reported new cases of porcine reproductive and respiratory syndrome.

R&D in porcine reproductive and respiratory syndrome is expected to offer lucrative growth opportunities for players in the porcine reproductive and respiratory syndrome vaccine market. For instance, in January 2021, a field research from Zoetis indicated that obtaining cycle threshold values based on processing fluids provides a practical way to identify nursery mortality associated with porcine reproductive and respiratory syndrome in neonatal pigs. Similarly, in October 2020, The Pirbright Institute, a research institute in U.K., announced to undertake two projects with ECO Animal Health Group plc, a pharmaceutical company based in the U.K., to develop vaccine candidates for porcine respiratory and reproductive syndrome virus.

Competitive Analysis 

Major players operating in the porcine reproductive and respiratory syndrome vaccine market include, Boehringer-Ingelheim GmbH, Zoetis, Pharmgate Animal Health, MSD Animal Health, Bioveta, Phibro Animal Health, Ceva , Ascent Corporation, Agrovet, Winsun Bio, Konipharm, Merck & Co., Inc., Elanco (Eli Lily and Company), and Ringpu (Tianjin) Bio-Pharmacy Co., Ltd.

Major players operating in the porcine reproductive and respiratory syndrome vaccine market are focused on approval and launch of new products to expand their product portfolio. For instance, in December 2020, Pharmgate Animal Health received the U.S. Department of Agriculture’s approval for PRRSGard, a modified-live vaccine, for the prevention of porcine reproductive and respiratory syndrome.  

Comments

Popular posts from this blog

Bourbon Whiskey Is the Most Popular Whiskey in America and In Many Other Countries around the World

Viral Vectors And Plasmid DNA Manufacturing Market Is Gaining Major Traction With Oxford Biomedica Plc Entering Into A 3-Year Agreement With Boehringer Ingelheim For The Manufacture And Supply Of Various Types Of Viral Vectors

Hard Surface Flooring Market Is Expected To Witness Robust Growth As Mohawk Industries Introduces Newly Imagined 30,000-Square Foot Floor Space At The International Surface Event (TISE)